Navigation Links
Hyperglycemia in Medical Technology

Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients

... (sugar) control for critical care patients with hyperglycemia (high blood glucose) does not improve outcomes ... national movement viewing the management of hyperglycemia in hospitals as a quality care measure," Dr. Etie ... and up-to-date recommendations for treatment of hyperglycemia in the hospital. "The central goal of the ...

New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer

... either with or without diabetes, developed hyperglycemia of grade 2 or higher (P=0.002 for diabetic ... (P=0.675). However, the development of hyperglycemia or hypercholesterolemia did not have affect on ... The use of TORISEL is likely to result in hyperglycemia and hyperlipemia. This may result in the need for ...

U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)

... TD may remit, partially or completely hyperglycemia and diabetes mellitus -- Hyperglycemia, in some ... testing. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. There have been few reports of hyperglycemia with ABILIFY ABILIFY may be associated with ...

FDA Advisory Committee Votes in Favor of Zyprexa for Two Adolescent Indications

... treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, palyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing. ...

RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder

... partially or completely, if antipsychotic treatment is withdrawn. hyperglycemia and Diabetes: Hyperglycemia, some cases extreme and associated with ... at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. ...

Diabetes Experts Issue New Recommendations for Inpatient Glycemic Control - Call for Systemic Changes in Hospitals Nationwide

... in ICU settings. "We are witnessing an evolution in the management of hyperglycemia in inpatient settings," Dr. Etie S. Moghissi, AACE Chair of the Inpatient ... to discharge from the hospital. "The responsibility for management of hyperglycemia shifts from the health care team to the patient following hospital ...

New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma

... during treatment with TORISEL. The use of TORISEL is likely to result in hyperglycemia and hyperlipemia. This may result in the need for an increase in the dose ... abnormalities (incidence greater than or equal to 30%) are anemia (94%), hyperglycemia (89%), hyperlipemia (87%), hypertriglyceridemia (83%), elevated alkaline ...

Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer

... during treatment with TORISEL. The use of TORISEL is likely to result in hyperglycemia and hyperlipemia. This may result in the need for an increase in the dose ... abnormalities (incidence greater than or equal to 30%) are anemia (94%), hyperglycemia (89%), hyperlipemia (87%), hypertriglyceridemia (83%), elevated alkaline ...

AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines

... of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. A potentially fatal ... (7% vs 5%). In long-term clinical trials of quetiapine, hyperglycemia (fasting glucose greater than or equal to 126 mg/dL) was observed in 10.7% ...

New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting

... of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. A potentially fatal ... (7% vs 5%). In long-term clinical trials of quetiapine, hyperglycemia (fasting glucose greater than or equal to 126 mg/dL) was observed in 10.7% ...

AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression

... of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. A potentially fatal ... (7% vs 5%). In long-term clinical trials of quetiapine, hyperglycemia (fasting glucose greater than or equal to 126 mg/dL) was observed in 10.7% ...

Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer

... during treatment with TORISEL. The use of TORISEL is likely to result in hyperglycemia and hyperlipemia. This may result in the need for an increase in the dose ... abnormalities (incidence greater than or equal to 30%) are anemia (94%), hyperglycemia (89%), hyperlipemia (87%), hypertriglyceridemia (83%), elevated alkaline ...

SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia

... of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. A potentially fatal ... hypotension (7% vs 5%). In long-term clinical trials of quetiapine, hyperglycemia (fasting glucose Greater Than or Equal To 126 mg/dl) was observed in 10.7% ...

Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions

... Monia, S. Bhanot. A Newly Identified Role of Nuclear Receptor Corepressor, SMRT (Silencing Mediator of Retinoid and Thyroid) in Improving hyperglycemia and Insulin Sensitivity in Obese and Diabetic Mice (Late-Breaking Poster) Authors: S.K. Pandey, S.F. Murray, S. Guo, L.M. Watts, S.L. Booten, ...

Boehringer Ingelheim Unveils Diabetes Pipeline

... 2 diabetes patients when added to onogoing metformin therapy. ADA, 05-09 June 2009, New Orleans, U.S.A. (2) Nathan DM et al. Medical Management of hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. Diabetes Care 21:1-11, 2008. (3) Clinicaltrials.gov. ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... adverse events were biliary disorders (62%), gastrointestinal disorders (14% to 38%), and injection-site pain (20% to 50%). Hypoglycemia (4%), hyperglycemia (27%), sinus bradycardia (19%), conduction abnormalities (9%), and arrhythmias (3%) have been reported. Additional adverse reactions identified in ...

FDA Issues a Complete Response Letter for Lilly's Olanzapine LAI for Treatment of Schizophrenia in Adults

... control; those with risk factors for diabetes should undergo baseline and periodic fasting blood glucose testing. Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing. Undesirable alterations in lipids have been observed with olanzapine ...

Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia

... vomiting (21%). The most common ( > 10%) Grade 3/4 adverse reactions were thrombocytopenia (28%), neutropenia (28%), elevated lipase (15%), and hyperglycemia (11%). In accelerated phase patients, the most commonly reported adverse reactions ( > 10%) were rash (28%), pruritus (20%), and constipation ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... and vomiting (21%). The most common (>10%) Grade 3/4 adverse reactions were thrombocytopenia (28%), neutropenia (28%), elevated lipase (15%) and hyperglycemia (11%). In accelerated phase patients, the most commonly reported adverse reactions (>10%) were rash (28%), pruritus (20%) and constipation (18%). ...

Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference

... who are starting on atypical antipsychotics should undergo baseline and periodic fasting blood glucose testing. Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing. Undesirable alterations in lipids have been observed with olanzapine use. Clinical ...

New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes

... diluted or mixed with any other insulin preparations or used in insulin infusion pumps. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Insulin may cause sodium retention and edema, particularly if previously poor metabolic ...

Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting

... and vomiting (21%). The most common ( >10%) Grade 3/4 adverse reactions were thrombocytopenia (28%), neutropenia (28%), elevated lipase (15%), and hyperglycemia (11%). In accelerated phase patients, the most commonly reported adverse reactions ( >10%) were rash (28%), pruritus (20%), and constipation (18%). ...

Drug Combo Could Lower Diabetes Complications and Costs

... diabetes have health implications for mother and child that extend far beyond pregnancy. However, for women with pre-existing diabetes, maternal hyperglycemia that exists prior to pregnancy and continues into the first 8 weeks of gestation exposes the fetus to an increased risk of miscarriage and birth ...

UMDNJ-University Hospital in Newark to Tailor Diabetes Interventions for Low-Income and Minority Groups With Grant From the International Diabetes Federation

... to the outpatient clinic facilitated by a diabetes care coordinator. Approximately 40% of adult hospitalized patient at University Hospital have hyperglycemia with only 5% receiving follow-up outpatient care in the diabetes clinic. The University Hospital's goal is to fill the gap in their diabetes care by ...

CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36

... newly diagnosed hyperglycemia (as defined by having an HbA1c of greater than 6.0 percent or a new fasting glucose of more than 110mg/dL). Worsening hyperglycemia (defined as greater than a one percent increase in HbA1c) was 37 percent less likely (p<0.001) in the Ranexa treated group and no increased ...

Hyperion Therapeutics Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of GT4P in Patients With Urea Cycle Disorders

... encephalopathy in patients with deficiencies in enzymes of the urea cycle. The most common adverse reactions are vomiting (9%), hypokalemia (7%), hyperglycemia (7%), convulsions (6%), and mental impairments (6%). Do not administer to patients with known hypersensitivity to sodium phenylacetate or ...

Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA

... with caution in patients with a known sulfonamide allergy. -- New onset diabetes mellitus, exacerbation of pre-existing diabetes mellitus, hyperglycemia and increased bleeding (in patients with hemophilia) have been reported in patients taking protease inhibitors. A causal relationship between ...

DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug

... Preclinical and clinical studies have suggested that a link exists between high cortisol levels and visceral adiposity, insulin resistance, and hyperglycemia -- common elements of T2DM and metabolic syndrome. There are no cortisol synthesis inhibitors on the market today, potentially making DIO-902 a ...

One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function

... M, Strumph P, Pimenta W, Veneman T, Jenssen T and Bolli G. "Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemia clamp." J Clin Endocrinol Metab 1992: 75(2), 379-382. 4 The International Diabetes Federation Diabetes Atlas. Available at: ....

One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function

... M, Strumph P, Pimenta W, Veneman T, Jenssen T and Bolli G. "Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemia clamp." J Clin Endocrinol Metab 1992: 75(2), 379-382. 4 The International Diabetes Federation Diabetes Atlas. Available at: ....

Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants

... treated with aripiprazole - hyperglycemia and diabetes mellitus-Hyperglycemia, in some ... testing. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. There have been few reports of hyperglycemia with aripiprazole Aripiprazole may be ...

Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia

... treated with aripiprazole -- hyperglycemia and diabetes mellitus -- Hyperglycemia, in some ... testing. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. There have been few reports of hyperglycemia with aripiprazole Aripiprazole may be ...

ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma

... dyspnea (20% vs 15%), tremor (20% vs 7%), decreased weight (18% vs 14%), thrombocytopenia (17% vs 10%), rash (16% vs 8%), back pain (15% vs 14%), hyperglycemia (15% vs 14%), and muscle weakness (15% vs 15%). Myelodysplastic Syndromes: Other adverse reactions reported in del 5q MDS patients (REVLIMID(R)): ...

New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia

... are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. Precautions include the risk of seizures, orthostatic hypotension, and cataracts. Examination of ...

Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer Treatment

... (6%); creatinine elevation (5%); alopecia (1%-13%); and dyspnea (1%-7%). The most common adverse events (all grades) were paresthesias (38%); hyperglycemia (30%); infection (18%-28%); and constipation (17%-28%). The most severe adverse events (grades 3/4) with GEMZAR plus carboplatin for the treatment ...

New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir

... diluted or mixed with any other insulin preparations or used in insulin infusion pumps. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Insulin may cause sodium retention and edema, particularly if previously poor metabolic ...

New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir

... or mixed with any other insulin preparations or used in insulin infusion pumps. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Insulin may cause sodium retention and edema, particularly if previously poor ...
Other Contents
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
(Date:7/28/2015)... ... July 28, 2015 , ... ... has authorized the Company, from time to time and depending on market conditions, ... up to $25 million. Repurchases will be made in open market or privately ...
(Date:7/28/2015)... ... July 28, 2015 , ... Fertility specialist Dr. Lisa Hasty of ... by Atlanta Magazine. In Atlanta Magazine's annual Top Doctors issue, Dr. Hasty has been ... and peers in the metro area as one of the most respected doctors in ...
(Date:7/28/2015)... CA (PRWEB) , ... July 28, 2015 , ... ... of Acute Coronary Syndromes (ACS-Heart Attack, Sudden Death, or Angina), many of whom ... cardiology is the identification of individuals with active yet undetected sub-clinical disease, who ...
(Date:7/28/2015)... ... July 28, 2015 , ... PeopleKeys ... the regional winner of the EY Entrepreneur of the Year award. The award ... of home healthcare, and the innovative work they have done in incorporating new ...
(Date:7/28/2015)... ... 2015 , ... Please join us for the 5th Annual Step for Hope 5K Run/Walk ... Avenue and Lies Road in Carol Stream. All are welcome. , Now in its ... and help to support individuals and families affected by a brain aneurysm. , “We ...
Breaking Medicine News(10 mins):Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2Health News:Receiving Recognition for Compassionate Care and Innovative Processes: Celtic Healthcare CEO Arnie Burchianti Wins Regional EY Entrepreneur of the Year Award 2Health News:Receiving Recognition for Compassionate Care and Innovative Processes: Celtic Healthcare CEO Arnie Burchianti Wins Regional EY Entrepreneur of the Year Award 3Health News:5th Annual Step for Hope 5K Run/Walk Event in Carol Stream, IL to Benefit Renowned Brain Aneurysm Foundation 2
Other TagsOther Tags